Farhad Ravandi, MD

Farhad Ravandi, MD, Professor in the Department of Leukemia, MD Anderson Cancer Center‎, discusses minimal residual disease. Ravandi says historically, MRD has shown a resistance to cytotoxic chemotherapy.

Farhad Ravandi, MD, The University of Texas MD Anderson Cancer Center, discusses the treatment of patients with relapse/refractory acute myeloid leukemia (AML).